Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Trial Profile

A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Suspended
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs LMB 100 (Primary) ; SEL-403 (Primary) ; Sirolimus (Primary)
  • Indications Mesothelioma; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Dec 2018 Status changed from recruiting to suspended as Grand 5 pneumonits occurred. as Per PI and FDA enrollment is hold.
    • 08 Sep 2018 Planned number of patients changed from 20 to 23.
    • 13 Mar 2018 Planned number of patients changed from 40 to 20.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top